aTyr Pharma (LIFE) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
August 15, 2022 4:00 PM EDTFirst sites initiated in Phase 3 EFZO-FIT study in patients with pulmonary sarcoidosis.
FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis.
Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments.
Company to host conference call and webcast today, May 15th, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery... More
